enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Growth Opportunities F. Forbion Buys 341,332 Shares of Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion purchased 341,332 shares of enGene stock in a transaction on Monday, September 30th. The stock was purchased at an average price of $6.34 per share, for a total transaction of $2,164,044.88. Following the completion of the transaction, the insider now owns 2,400,791 shares of the company’s stock, valued at approximately $15,221,014.94. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

enGene Price Performance

Shares of ENGN stock opened at $9.02 on Friday. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $398.38 million, a price-to-earnings ratio of -5.24 and a beta of -0.69. The firm’s 50 day moving average is $6.71 and its 200-day moving average is $9.78. enGene Holdings Inc. has a 1 year low of $4.42 and a 1 year high of $43.00.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Sell-side analysts forecast that enGene Holdings Inc. will post -1.56 EPS for the current fiscal year.

Institutional Trading of enGene

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Altitude Crest Partners Inc. bought a new stake in enGene during the 1st quarter worth about $2,039,000. SR One Capital Management LP bought a new stake in shares of enGene during the second quarter worth approximately $4,715,000. Janus Henderson Group PLC bought a new stake in shares of enGene during the first quarter worth approximately $17,095,000. Finally, Logos Global Management LP lifted its holdings in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares during the period. 64.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ENGN shares. Oppenheimer reissued an “outperform” rating and issued a $30.00 target price on shares of enGene in a report on Tuesday, September 24th. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $33.67.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.